Loran O B, Segal A S, Shcheplev P A
Urol Nefrol (Mosk). 1995 Jul-Aug(4):35-8.
Intracavernous injections (ICI) of prostaglandin E1 (PGE1) of German produce (Schwarz Pharma A. G.) have been tested for diagnosis of erectile disorders in 63 patients (age 32-71, the majority at the age 45-65) and for autotherapy in 22 patients. In 76% of males with erectile impotency PGE1 ICI in a dose 10-20 micrograms result in marked erection which emerged within 5-15 min after the injection and persisted for 90 min on the average in spite of ejaculation. 86% of patients suffering from erectile dysfunction found this method of impotency correction satisfactory as it warrants normal coitus in 91% of cases (dose regimen 10-20 micrograms). ICI of PGE1 in the above dose 1-2 times a week for 2 months is safe, entail no systemic and insignificant local side effects. The risk of priapism and cavernous body fibrosis is minimal. The duration of the effect is related to the dose. The above advantages make PGE1 superior to papaverin and phentolamine. PGE1 ICI are recommended as the treatment of choice for therapy of erectile dysfunctions.
已对德国产（施瓦茨制药股份公司）前列腺素E1（PGE1）进行海绵体内注射（ICI），以诊断63例患者（年龄32 - 71岁，多数为45 - 65岁）的勃起功能障碍，并对22例患者进行自我治疗。在76%的勃起功能障碍男性中，10 - 20微克剂量的PGE1 ICI可导致明显勃起，注射后5 - 15分钟内出现，平均持续90分钟，即使射精后仍持续。86%患有勃起功能障碍的患者认为这种性功能障碍矫正方法令人满意，因为在91%的病例中（剂量方案为10 - 20微克）可保证正常性交。上述剂量的PGE1 ICI每周1 - 2次，持续2个月是安全的，不会引起全身副作用，局部副作用也不明显。阴茎异常勃起和海绵体纤维化的风险极小。效果持续时间与剂量有关。上述优点使PGE1优于罂粟碱和酚妥拉明。推荐PGE1 ICI作为治疗勃起功能障碍的首选疗法。
